Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results

MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2008.

The net loss for the first quarter ended March 31, 2008 was $14.3 million compared with $6.7 million during the same period in 2007. As of March 31, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $81.1 million.

First Quarter Financial Results

Research and development expenses for the first quarter ended March 31, 2008 were $11.8 million compared to $4.5 million for the same period in 2007. The increase in research and development expenses for the first quarter of 2008 was primarily related to increases in clinical trial expenses, personnel expenses to support Phase 3 clinical programs related to MAP Pharmaceuticals' two lead product candidates, and the attainment of a milestone related to the UDB program.

Sales, general and administrative expenses for the first quarter ended March 31, 2008 were $3.1 million compared to $1.7 million for the same period in 2007. The increase in sales, general and administrative expenses for the first quarter of 2008 was primarily related to increases in personnel expenses, share-based compensation and professional services.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of March 31, 2008 of $81.1 million, compared to $95.0 million as of December 31, 2007. In addition, for the first quarter ended March 31, 2008, non-cash share-based compensation and depreciation was approximately $1.1 million.

"We are pleased with the progress we have made during the first quarter," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "For our Unit Dose Budesonide program for pediatric asthma, we initiated our first Phase 3 clinical trial and reported positive results from a Phase 2 pharmacokinetic trial comparing UDB to the currently marketed conventional nebulized budesonide. For our MAP0004 migraine program, we received a special protocol assessment (SPA) from the FDA, conducted investigator meetings and initiated clinical sites. We are working on manufacturing and qualification of clinical supplies with our external commercial manufacturing partners and upon completion of this work we expect to initiate this Phase 3 trial. Finally, we reported positive results from yet a third clinical program in a Phase 2a trial for MAP0005, a combination steroid and beta agonist product candidate."

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to our MAP0004 migraine program. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the manufacture and qualification of clinical supply materials, our reliance on third-party manufacturers and the commencement, enrollment and conduct of clinical trials. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K, filed with the SEC on March 20, 2008, and available at


(a development stage enterprise)


(In thousands)


March 31, December 31,

2008 2007


Current assets:

Cash, cash equivalents and short-term

investments $81,071 $94,990

Other current assets 859 1,079

Total current assets 81,930 96,069

Property and equipment, net 4,543 4,183

Restricted cash 321 321

Other assets 98 122

Total assets $86,892 $100,695

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $9,303 $8,912

Current portion of long-term debt 4,138 3,820

Total current liabilities 13,441 12,732

Long-term debt, less current portion 5,277 6,357

Total liabilities 18,718 19,089

Total stockholders' equity 68,174 81,606

Total liabilities and stockholders' equity $86,892 $100,695


(a development stage enterprise)


(In thousands, except share and per share amounts)


Three Months Ended

March 31,

2008 2007

Operating expenses:

Research and development $11,815 $4,517

Sales, general and administrative 3,140 1,749

Total operating expenses 14,955 6,266

Loss from operations (14,955) (6,266)

Other income (expense), net 655 (393)

Net loss (14,300) (6,659)

Cumulative stock dividend

attributable to preferred

stockholders - (1,384)

Net loss attributable to common

stockholders $(14,300) $(8,043)

Net loss per share attributable to

common stockholders, basic and diluted $(0.71) $(10.77)

Weighted-average common shares used in

computing net loss per share

attributable to common stockholders,

basic and diluted 20,209,739 746,815

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology: